The Harvard NeuroDiscovery Center Biomarker Study aims to discover and validate biomarkers for neurodegenerative diseases.
Samples and clinical data will be made available to approved investigators within the Harvard NeuroDiscovery Center research community. To begin the process, a letter of intent outlining the hypothesis being proposed, its significance, the reason for proposing use of specimens and required covariate data should be sent to Nancy Maher, Senior Project Manager, Harvard NeuroDiscovery Center Biomarkers Study. Letters of intent can be submitted at any time throughout the year.
Clinical data collected includes physician exam measuring disease activity and severity. Additional data is collected through study staff interview and self-administered questionnaires and includes medical history, medication use, risk factor data, family history of neurologic diseases, co-morbidities, smoking history and caffeine intake. Also included are standardized scales measuring quality of life, depression and physical functioning.
Blood samples from biomarker participants are transported at room temperature to the Scherzer laboratory for processing within 4 hours of blood draw, centrifuged and aliquotted into plasma, packed red blood cells, buffy coat and serum and stored at -80°. Samples collected in PAXgene tubes are transferred at room temperature to the Scherzer laboratory and placed at -4° within 4 hours of the blood draw. RNA is processed within 3-5 days by the biospecimen manager using the PreAnalytix protocol. One tube is sent to the Gusella laboratory at for cell line transformation and storage.